Pub-2018

Title
Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia
Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with Waldenström Macroglobulinemia
Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia
iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia
The real world of Waldenström's macroglobulinaemia
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia
Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Genomic Landscape of Waldenström Macroglobulinemia
Initial Evaluation of the Patient with Waldenström Macroglobulinemia
Waldenström Macroglobulinemia: Lessons Learned from Basic and Clinical Research
Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients
MYD88 mutated and wild-type Waldenströms Macroglobulinemia: Characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4
Extracellular vesicle-mediated transfer of constitutively active MyD88L265P engages MyD88supwt and activates signaling
Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia
BTK Cys481Ser drives ibrutinib resistance via ERK1/2, and protects BTK Wild-Type MYD88 mutated cells by a paracrine mechanism
Ibrutinib Withdrawal Symptoms in Patients with Waldenström Macroglobulinemia
Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia
Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia
Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival